Literature DB >> 24307792

Splanchnic-aortic inflammatory axis in experimental portal hypertension.

Maria-Angeles Aller1, Natalia de las Heras, Maria-Paz Nava, Javier Regadera, Jaime Arias, Vicente Lahera.   

Abstract

Splanchnic and systemic low-grade inflammation has been proposed to be a consequence of long-term prehepatic portal hypertension. This experimental model causes minimal alternations in the liver, thus making a more selective study possible for the pathological changes characteristic of prehepatic portal hypertension. Low-grade splanchnic inflammation after long-term triple partial portal vein ligation could be associated with liver steatosis and portal hypertensive intestinal vasculopathy. In fact, we have previously shown that prehepatic portal hypertension in the rat induces liver steatosis and changes in lipid and carbohydrate metabolism similar to those produced in chronic inflammatory conditions described in metabolic syndrome in humans. Dysbiosis and bacterial translocation in this experimental model suggest the existence of a portal hypertensive intestinal microbiome implicated in both the splanchnic and systemic alterations related to prehepatic portal hypertension. Among the systemic impairments, aortopathy characterized by oxidative stress, increased levels of proinflammatory cytokines and profibrogenic mediators stand out. In this experimental model of long-term triple portal vein ligated-rats, the abdominal aortic proinflammatory response could be attributed to oxidative stress. Thus, the increased aortic reduced-nicotinamide-adenine dinucleotide phosphate [NAD(P)H] oxidase activity could be associated with reactive oxygen species production and promote aortic inflammation. Also, oxidative stress mediated by NAD(P)H oxidase has been associated with risk factors for inflammation and atherosclerosis. The splanchnic and systemic pathology that is produced in the long term after triple partial portal vein ligation in the rat reinforces the validity of this experimental model to study the chronic low-grade inflammatory response induced by prehepatic portal hypertension.

Entities:  

Keywords:  Aortopathy; Hepatic steatosis; Inflammation; Portal hypertension

Mesh:

Substances:

Year:  2013        PMID: 24307792      PMCID: PMC3848146          DOI: 10.3748/wjg.v19.i44.7992

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  50 in total

1.  The risk association between experimental portal hypertension and an aortic atherosclerosis-like disease.

Authors:  Natalia De las Heras; Maria-Angeles Aller; Jaime Arias; Vicente Lahera
Journal:  Hepatology       Date:  2012-09-20       Impact factor: 17.425

Review 2.  Animal models of portal hypertension.

Authors:  Juan-G Abraldes; Marcos Pasarín; Juan-Carlos García-Pagán
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

Review 3.  Portal hypertension and its complications.

Authors:  Arun J Sanyal; Jaime Bosch; Andres Blei; Vincente Arroyo
Journal:  Gastroenterology       Date:  2008-05       Impact factor: 22.682

4.  A wound-like inflammatory aortic response in chronic portal hypertensive rats.

Authors:  Natalia de Las Heras; María-Angeles Aller; Beatriz Martín-Fernández; María Miana; Sandra Ballesteros; Javier Regadera; Victoria Cachofeiro; Jaime Arias; Vicente Lahera
Journal:  Mol Immunol       Date:  2012-03-29       Impact factor: 4.407

5.  Allopurinol reduces bacterial translocation, intestinal mucosal lipid peroxidation, and neutrophil-derived myeloperoxidase activity in chronic portal hypertensive and common bile duct-ligated growing rats.

Authors:  G Schimpl; P Pesendorfer; G Steinwender; G Feierl; M Ratschek; M E Höllwarth
Journal:  Pediatr Res       Date:  1996-09       Impact factor: 3.756

6.  Possible mechanisms involved in the discrepancy of hepatic and aortic endothelial nitric oxide synthases during the development of cirrhosis in rats.

Authors:  Morvarid Shir Mohammadi; Dominique Thabut; Dominique Cazals-Hatem; Arnaud Galbois; Marika Rudler; Dominique Bonnefont-Rousselot; Richard Moreau; Didier Lebrec; Khalid A Tazi
Journal:  Liver Int       Date:  2009-11-27       Impact factor: 5.828

7.  Measurement of portal-systemic shunting in the rat by using gamma-labeled microspheres.

Authors:  M Chojkier; R J Groszmann
Journal:  Am J Physiol       Date:  1981-05

8.  Bacterial translocation in the portal-hypertensive rat: studies in basal conditions and on exposure to hemorrhagic shock.

Authors:  W T Sorell; E M Quigley; G Jin; T J Johnson; L F Rikkers
Journal:  Gastroenterology       Date:  1993-06       Impact factor: 22.682

Review 9.  Translational mini-review series on immunology of vascular disease: accelerated atherosclerosis in vasculitis.

Authors:  J W Cohen Tervaert
Journal:  Clin Exp Immunol       Date:  2009-03-20       Impact factor: 4.330

10.  Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity.

Authors:  Jorge Henao-Mejia; Eran Elinav; Chengcheng Jin; Liming Hao; Wajahat Z Mehal; Till Strowig; Christoph A Thaiss; Andrew L Kau; Stephanie C Eisenbarth; Michael J Jurczak; Joao-Paulo Camporez; Gerald I Shulman; Jeffrey I Gordon; Hal M Hoffman; Richard A Flavell
Journal:  Nature       Date:  2012-02-01       Impact factor: 49.962

View more
  4 in total

1.  Liver resection and metabolic disorders: an undescribed mechanism leading to postoperative mortality.

Authors:  Alban Zarzavadjian Le Bian; Renato Costi; Mohamed Said Sbai-Idrissi; Claude Smadja
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

2.  Increases in Autoantibody Level Associated with Degenerative Changes in the Intestinal Mucosa in Liver Cirrhosis.

Authors:  Radmila V Karpova; Ksenia S Russkova; Yuliya N Lavrentieva
Journal:  Clin Exp Gastroenterol       Date:  2020-08-26

3.  Peripheral and Hepatic Vein Cytokine Levels in Correlation with Non-Alcoholic Fatty Liver Disease (NAFLD)-Related Metabolic, Histological, and Haemodynamic Features.

Authors:  Luisa Vonghia; Thea Magrone; An Verrijken; Peter Michielsen; Luc Van Gaal; Emilio Jirillo; Sven Francque
Journal:  PLoS One       Date:  2015-11-24       Impact factor: 3.240

Review 4.  Portal hypertension as immune mediate disease.

Authors:  Sara Manti; Lucia Marseglia; Gabriella D'Angelo; Martina Filippelli; Caterina Cuppari; Eloisa Gitto; Claudio Romano; Teresa Arrigo; Carmelo Salpietro
Journal:  Hepat Mon       Date:  2014-06-07       Impact factor: 0.660

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.